2022 American Transplant Congress
Establishment of an In Vitro Assay to Evaluate Indirect T-cell Allo-Response Using Donor PBMC-Pulsed Dendritic Cells
*Purpose: Conventional MLR-based methods which evaluate donor-specific immune response via direct T-cell recognition pathway have been reported to be useful in predicting acute TCMR. However,…2022 American Transplant Congress
A Novel Approach to Non-Invasive Multimodality Testing with Allosure and Allomap Predicts Microvascular Inflammation with High Accuracy in Kidney Transplant Recipients
University of Wisconsin, Madison, WI
*Purpose: The most prominent histologic lesion in antibody-mediated rejection (ABMR) is microvascular inflammation (MVI); however, its recognition and scoring can be challenging and poorly reproducible…2022 American Transplant Congress
The Correlation of Dd-cfdna and Donor Specific Antibodies in Kidney Transplant Recipients
Johns Hopkins Hospital, Baltimore, MD
*Purpose: Donor derived cell free DNA (dd-cfDNA) is increasingly being utilized to discern the presence of rejection in kidney transplant recipients (KTRs). There continues to…2022 American Transplant Congress
Monitoring of Kidney Allograft Rejection Using Patient-Centric State-of-the-Art Tools – An Approach to Early Diagnosis and Intervention
*Purpose: The early detection and timely management of kidney allograft rejection using traditional markers including serum creatinine (SCr) has been inadequate due to lagging response.…2022 American Transplant Congress
Prospective Analysis of the Impact of Impella 5.5 Devices on HLA Antibody Development in Transplant Recipients
Heart and lung Transplant Research, Baylor University Medical Center, Dallas, TX
*Purpose: Little is known about the development of Human Leukocyte Antigen antibodies with the use of the new Impella 5.5 temporary mechanical circulatory assist device.*Methods:…2022 American Transplant Congress
Elevated Donor-Derived Cell-Free DNA (dd-cfDNA) in the Early Post-Transplant Period is Associated with an Increased Incidence of Adverse Clinical Outcomes in Kidney Transplant Recipients
*Purpose: Early post-transplant elevations in dd-cfDNA, even in the absence of histologic rejection or other overt pathology, have been suggested to carry a risk of…2022 American Transplant Congress
De Novo DSA in the Setting of Stable Allograft Function is a Benign Finding
Houston Methodist Hospital, Houston, TX
*Purpose: We sought to determine the long-term outcome of renal allografts that developed de novo DSA (dnDSA) in the setting of stable renal function.*Methods: A…2022 American Transplant Congress
Use The Vascularized Sentinel Skin Flap For Prophylaxis Of Antibody-mediated Rejection After Kidney Transplantation In Highly Sensitized Patients
*Purpose: Patients with high titer of preexisting donor specific anti-HLA antibodies (DSA) have very high risk of antibody mediated rejection development and followed by the…2022 American Transplant Congress
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation
*Purpose: In this study, we aimed to identify the risk factors contributing to the development of donor-specific anti-HLA antibody (DSA) during long-term follow-up of patients…2022 American Transplant Congress
LGALS1 is Expressed in Glomerular Endothelial Cells and Induced Upon Stimulation with Anti-HLA Antibody
*Purpose: Antibody-mediated rejection (AMR) accounts for >50% of premature kidney graft loss. AMR is caused by donor specific antibodies (DSA) against human leukocyte antigens (HLA)…
- 1
- 2
- 3
- …
- 47
- Next Page »